CLINEXEL provides regulatory affairs services in India and international markets, supporting pharmaceutical, biotechnology and medical device companies with regulatory strategy, clinical development planning, dossier preparation, regulatory submissions and interactions with health authorities.
Our regulatory experts support sponsors from early development and pre-submission planning through clinical trial approvals, marketing applications, regulatory responses and lifecycle management.
With experience across India, the US, Europe and other international regulatory environments, CLINEXEL helps sponsors develop practical regulatory strategies aligned with their product, development stage and target markets.
Regulatory requirements influence clinical development strategy, study design, submission planning and market access.
CLINEXEL combines regulatory knowledge with practical experience in clinical development and CRO operations.
CLINEXEL supports regulatory activities involving India and international markets, including experience with US FDA, European and Indian regulatory environments. Its leadership team has experience interacting with regulators including US FDA, EMA, MHRA and authorities in India and other countries.
Because CLINEXEL is a full-service CRO, regulatory strategy can be coordinated with clinical development, clinical operations, medical writing and pharmacovigilance.
CLINEXEL's Head of Regulatory Affairs, Shivani Nayak, has experience working with CDSCO as well as within the pharmaceutical industry and has worked on clinical trial, pre-IND, IND and marketing authorization dossiers.
Our regulatory approach considers the relationship between product development, clinical evidence, regulatory requirements and submission strategy.
CLINEXEL positions its regulatory and clinical development services around efficient strategies and cost optimization where appropriate.
CLINEXEL provides regulatory support across the product development lifecycle.
Our services include:
A regulatory strategy should be established early in product development rather than only when a submission is approaching.
The strategy can be tailored according to the product type, development stage, available clinical evidence and target market.
CLINEXEL supports sponsors with:
CLINEXEL provides integrated clinical-regulatory strategy to help sponsors evaluate:
Regulatory decisions can directly influence clinical development plans.
CLINEXEL’s global clinical development offering specifically describes development of clinical development plans and coordination of pre-IND, End-of-Phase and pre-NDA meetings.
Early interaction with regulatory authorities can help sponsors clarify development expectations and regulatory questions.
CLINEXEL supports:
Support for preparation and coordination of scientific advice interactions with relevant regulatory authorities.
Support for regulatory discussions relating to clinical development progress and subsequent development plans.
CLINEXEL’s current regulatory page specifically identifies pre-IND dossier preparation and coordination of pre-IND/scientific advice meetings.
CLINEXEL supports preparation, compilation and review of regulatory dossiers according to the applicable submission pathway and market requirements.
Services may include:
The precise dossier format and content are determined by the target authority and application type.
CLINEXEL supports regulatory activities associated with clinical trial initiation and ongoing regulatory requirements.
For India, CLINEXEL supports sponsors navigating the country’s clinical trial regulatory framework, including CDSCO-related processes. Its published India regulatory material describes CDSCO as India’s Central Licensing Authority and discusses the NDCT Rules, ethics oversight and the SUGAM submission process.
Services include:
India is an important market for pharmaceutical, biotechnology and medical device development.
CLINEXEL provides regulatory affairs services in India for sponsors requiring local regulatory support and coordination.
Our India-focused regulatory capabilities can support:
CLINEXEL is a CDSCO-registered CRO and has experience supporting clinical research and regulatory activities in India.
India’s regulatory environment includes the New Drugs and Clinical Trials Rules, 2019, Medical Devices Rules, 2017 and related regulatory and ethical requirements. CLINEXEL has published detailed material explaining India’s clinical trial regulatory framework and CDSCO/SUGAM processes.
For international sponsors conducting studies in India, CLINEXEL can coordinate local regulatory activities with broader global clinical development plans.
Pharmaceutical and biotechnology companies increasingly develop products for multiple markets.
Each jurisdiction may have different regulatory procedures, submission requirements and post-approval obligations.
CLINEXEL provides global regulatory affairs support for international development programs.
Our regulatory experience includes:
Support relating to:
Support relating to:
Support involving:
Support for applicable UK clinical and regulatory requirements.
Regulatory strategy and coordination can be extended to additional markets through CLINEXEL’s international network and qualified partners where appropriate.
CLINEXEL’s global clinical development model states that it supports clinical trial applications in the US, EU and India and works with local CROs through AICROS for multiregional development.
CLINEXEL supports sponsors in preparing for and coordinating interactions with regulatory authorities.
CLINEXEL’s leadership has experience interacting with US FDA, EMA, MHRA, Health Canada, WHO, TGA and other regulatory authorities.
This may include:
CLINEXEL supports:
Regulatory review can result in questions, information requests or deficiencies requiring scientifically and regulatorily appropriate responses.
Our regulatory and medical writing teams can work together where responses require clinical, scientific or medical documentation.
Regulatory responsibilities continue after initial approval.
CLINEXEL supports applicable lifecycle activities including:
The current CLINEXEL regulatory page specifically identifies supplemental NDA/subsequent IND support for lifecycle management involving new formulations and indications, as well as package insert development and updates.
Clear and compliant product information is an important component of regulatory submissions and ongoing product lifecycle management.
CLINEXEL supports:
Our existing Regulatory Affairs service specifically identifies new package insert development, maintenance and updates.
CLINEXEL provides regulatory gap analysis covering areas such as:
This can help identify potential gaps before formal submission.
Before submitting to a regulatory authority, sponsors can benefit from an assessment of the available documentation against the intended submission pathway.
CLINEXEL also supports regulatory and clinical requirements associated with medical devices.
CLINEXEL’s broader service offering identifies medical device clinical trials, PMCF studies for CE marking and clinical/biological/performance evaluation documentation.
CLINEXEL supports pharmaceutical and biotechnology companies across different stages of product development.
Regulatory pathway planning, pre-IND strategy and clinical development planning.
Clinical trial regulatory submissions, authority interactions and ongoing regulatory requirements.
Dossier preparation, submission support and regulatory authority responses.
Lifecycle management, variations, labeling updates and other applicable regulatory activities.
This creates a continuous regulatory pathway from development → clinical trials → registration → post-approval.
We understand the product, development stage, available evidence and target markets.
The applicable regulatory pathway and development strategy are assessed.
Available documentation and evidence are evaluated against the intended regulatory pathway.
Regulatory milestones, documentation and submission requirements are mapped.
Required regulatory documentation is prepared, compiled and reviewed.
Submissions are coordinated according to the applicable authority and procedure.
Queries, information requests and regulatory communications are coordinated.
Post-approval regulatory activities, variations, labeling changes and other lifecycle requirements are managed as applicable.
Regulatory strategy is strongest when it is connected with the scientific and clinical development program.
CLINEXEL combines:
Regulatory strategy, submissions and authority interactions.
Clinical development planning and clinical trial execution.
Clinical and regulatory document preparation.
Safety and post-marketing regulatory requirements.
Practical understanding of study implementation and site requirements.
This integrated CRO model allows regulatory considerations to be incorporated into broader development planning. CLINEXEL describes its services as spanning clinical development, clinical operations, regulatory affairs, medical writing and pharmacovigilance.
CLINEXEL’s regulatory function is led by professionals with pharmaceutical and regulatory experience.
CLINEXEL’s broader leadership team includes professionals with extensive pharmaceutical and biotechnology industry experience.
Its Head of Regulatory Affairs, Shivani Nayak, has experience with CDSCO as well as pharmaceutical industry regulatory activities and has worked on clinical trial, pre-IND, IND and marketing authorization dossiers.
Regulatory affairs services help pharmaceutical, biotechnology and medical device companies navigate regulatory requirements throughout product development, clinical research, registration and post-approval lifecycle management.
A regulatory affairs consultant can support regulatory strategy, pathway assessment, dossier preparation, submissions, health authority interactions, query responses and lifecycle management.
Yes. CLINEXEL provides regulatory affairs support in India, including CDSCO-related clinical trial and drug regulatory activities. CLINEXEL is a CDSCO-registered CRO.
Yes. CLINEXEL supports regulatory activities involving India, the US, Europe and other international markets through its regulatory expertise and global CRO network.
Yes. CLINEXEL provides pre-IND dossier preparation and coordination for pre-IND and scientific advice meetings.
Yes. CLINEXEL supports preparation, compilation and review of regulatory dossiers according to the applicable product and submission pathway.
CLINEXEL’s leadership and regulatory team have experience interacting with US FDA and European regulatory authorities, and the company provides global clinical-regulatory support.
Yes. CLINEXEL supports medical device clinical and regulatory documentation, including clinical evaluation and performance-related documentation and EU MDR-related activities.
Yes. Its regulatory service offering includes supplemental NDA/subsequent IND activities, new formulations and indications, and package insert maintenance and updates.
Whether you are preparing a clinical trial application, pre-IND meeting, IND, marketing application, regulatory response or post-approval change, CLINEXEL can support your regulatory strategy and execution in India and international markets.
Talk to our regulatory affairs team about your product, development stage and target markets.